Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PANTOPRAZOLE MAGNESIUM

All products: general benefit

Other products in the same Health Canada class (A02BC) — coverage varies; not interchangeable

  • Rabeprazole (Pariet): general benefit
  • Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
  • Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, Not a benefit
  • Pantoprazole (Pantoloc): limited Use 293, 295, 297, 401, 402, Not a benefit
  • Dexlansoprazole (Dexilant): not a benefit
  • Esomeprazole (Nexium DR Tab): not a benefit

7 more in the class list below

Tecta · DIN 02267233 · 40mg · Ent Coated tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Tecta (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Tecta · DIN 02267233 Manufacturer: Nycomed Canada Inc.; listing date 2010-06-14 Health Canada: Marketed since 2013-06-21 · brand TECTA · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) 40 MG · company Takeda canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75263 · Verify on the e-Formulary ↗ (DIN 02267233)

Source record
DIN 02267233: Tecta Raw flags: chronicUseMed=Y, sec3=Y Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id NYC Source form: Ent Coated Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8260; ministry $0.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02267233 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75263
Interchangeable products
Mylan-Pantoprazole T · DIN 02408570 · $0.1875 Pantoprazole Magnesium · DIN 02441853 · $0.1875 Pantoprazole T · DIN 02466147 · $0.1875 Pantoprazole T · DIN 02519534 · $0.1875 Teva-Pantoprazole Magnesium · DIN 02440628 · $0.1875
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap

ESOMEPRAZOLE

· 22 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 20mg · DR Tab

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conditions where a reduction of gastric acid secretion is required
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: RABEPRAZOLE SODIUM RABEPRAZOLE SODIUM · General benefit 1 INDICATIONS PARIET ® (rabeprazole sodium) is indicated for treatment of conditions where a reduction of gastric acid secretion is required, such as:  Symptomatic relief and healing of erosive or ulcerative gastroesophageal reflux disease (GERD).  Long-term maintenance of healing of erosive or ulcerative gastroesophageal reflux disease (GERD).  Treatment of symptoms (i.e., heartburn and regurgitation) in symptomatic gastroesophageal reflux disease (GERD), also called non-erosive reflux disease (NERD).  Symptomatic relief and healing of duodenal ulcers.  Symptomatic relief and healing of gastric ulcers.  Long-term treatment of pathological hypersecretory conditions, including Zollinger - Ellison syndrome.  Eradication of Helicobacter pylori (H. pylori) associated with duodenal ulcer disease (active or history within the past 5 years). PM: https://pdf.hres.ca/dpd_pm/00066947.PDF; date May 7, 2001; DIN 02243796; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS TECTA® (pantoprazole magnesium) is indicated for the treatment of conditions where a reduction of gastric acid secretion is required, such as the following: • Duodenal ulcer • Gastric ulcer • Reflux esophagitis • Symptomatic gastro-esophageal reflux disease (such as, acid regurgitation and heartburn) • Helicobacter pylori (H. pylori) associated duodenal ulcer Pantoprazole, in combination with clarithromycin and either amoxicillin or metronidazole, is indicated for the treatment of patients with an active duodenal ulcer who are H. pylori positive (see 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS). Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. Geriatrics Geriatrics (> 65 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TECTA® in geriatric patients has been established; therefore, Health Canada has authorized all indications for geriatric use (see 4 DOSAGE AND ADMINISTRATION; 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00070181.PDF PM date: MAR 30, 2023 Source product: TECTA; DIN 02267233; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.